{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:01:33Z","timestamp":1790085693470,"version":"4.0.1"},"reference-count":15,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience increased signs and symptoms of their underlying disease when vaccinated against meningococcal disease before receiving complement component 5 inhibitor therapies. This retrospective analysis indicated an overall low relapse incidence (mean [range], 3.3% [0.7%\u201310.6%]) of physician\u2010reported relapses occurring within 4\u2009weeks of meningococcal vaccination in those screened in CHAMPION\u2010NMOSD (NCT04201262), randomized to eculizumab or placebo in PREVENT (NCT01892345), and from the Japanese postmarketing surveillance of eculizumab in patients with anti\u2010aquaporin\u20104 antibody\u2010positive NMOSD. Further studies are needed to determine if postvaccination relapses are attributable to vaccination or inherent relapse risk among these patients.<\/jats:p>","DOI":"10.1002\/acn3.70353","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:39:46Z","timestamp":1773211186000},"page":"1488-1492","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low Incidence of Relapses After Vaccination in Anti\u2010Aquaporin\u20104 Antibody\u2010Positive\n                    <scp>NMOSD<\/scp>"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J.","family":"Pittock","sequence":"first","affiliation":[{"name":"Department of Neurology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5858-0998","authenticated-orcid":false,"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Neurology Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Parks","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Clinical Development  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Allen","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Biostatistics  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7221-6365","authenticated-orcid":false,"given":"Sami","family":"Fam","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Global Medical Affairs Neurology  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(07)70216\u20108"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231181177"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.4161\/viru.26515"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2007.03.005"},{"key":"e_1_2_11_9_1","unstructured":"Alexion Pharmaceuticals Inc \u201cSoliris (Eculizumab). Summary of Product Characteristics \u201d(2025)."},{"key":"e_1_2_11_10_1","unstructured":"Alexion Pharmaceuticals Inc \u201cUltomiris (Ravulizumab). Summary of Product Characteristics \u201d(2025)."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209888"},{"issue":"3","key":"e_1_2_11_12_1","first-page":"E140","article-title":"Meningococcal B Vaccine and the Vision of a Meningitis Free World","volume":"56","author":"Bianchi A.","year":"2015","journal-title":"Journal of Preventive Medicine and Hygiene"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014\u20104015"},{"key":"e_1_2_11_14_1","unstructured":"A.Berthele I.Ayzenberg G.Lindenblatt et\u00a0al. \u201cRe: Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort. Response Letter \u201d(2024) https:\/\/www.neurology.org."},{"key":"e_1_2_11_15_1","unstructured":"J.Nakahara I.Nakashima H.Yokote et\u00a0al. Long\u2010Term Safety Effectiveness and Corticosteroid Sparing Effects of Eculizumab in Patients With AQP4\u2010Ab+ Neuromyelitis Optica Spectrum Disorder: Real\u2010World Data From Japan. Presented at the 40th Congress of the European Committee for Teatment and Reasearch in Multiple Sclerosis (ECTRIMS); September 18\u201020 2024; Copenhagen Denmark. Poster P025."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010023\u201011910\u2010z"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.70353","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:47:42Z","timestamp":1783928862000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.70353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/acn3.70353"],"URL":"https:\/\/doi.org\/10.1002\/acn3.70353","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"2025-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}